Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
10:59:04 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



E:CYBN - CYBIN INC. - http://www.cybin.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CYBN - E  37.50.49·0.5346.50.52214.01012240.50  0.52  0.4950.98  0.3016:18:26Apr 1815 min RT 2¢
NEO exchange - E37.50.49·0.5346.50.52181.4871260.50  0.52  0.4950.98  0.3016:18:2615 min
Omega - O 0.51-0.01-1.913.56100.50  0.51  0.5015:29:4415 min
Chi-X - X 0.50-0.02-3.83.0140.50  0.51  0.5015:59:0215 min
CX2 - H 0.51-0.01-1.98.0490.50  0.51  0.5015:29:4415 min
CXD - D 0.523.0122    Mar 2815 min
TriAct - M 0.525.1153    15 min

Recent Trades - Last 10 of 224
Time ETExPriceChangeVolumeBuyerSellerMarkers
16:18:26E0.52 0301 NEO Buy301 NEO BuyZ
15:59:59E0.52 50079 CIBC7 TD SecK
15:59:59E0.51-0.0150079 CIBC80 National BankK
15:59:59E0.51-0.0150079 CIBC19 DesjardinsK
15:59:59E0.51-0.0150079 CIBC19 DesjardinsK
15:59:59E0.51-0.0150079 CIBC19 DesjardinsK
15:59:02X0.50-0.0250079 CIBC124 QuestradeK
15:59:02E0.50-0.021,50079 CIBC124 QuestradeK
15:59:01E0.51-0.0150013 Instinet2 RBCK
15:59:01E0.51-0.0150013 Instinet2 RBCK

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2024-04-18 13:00C:CYBN0.51News ReleaseCybin publishes CYB210010 research manuscript
2024-04-16 12:27C:CYBN0.51News ReleaseCybin receives depressive disorder therapy patent
2024-04-08 07:12C:CYBN0.55In the NewsGlobe says MindMed, Cybin get nod from U.S. FDA
2024-03-19 12:42C:CYBN0.61News ReleaseCybin closes $150-million (U.S.) private placement
2024-03-15 09:12C:CYBN0.61News ReleaseCybin begins phase 2 CYB004 study for GAD treatment
2024-03-14 11:30C:CYBN0.58News ReleaseCybin talks CYB003 phase 2 FDA meeting, phase 3 design
2024-03-13 09:16C:CYBN0.58News ReleaseCybin arranges $150-million (U.S.) private placement
2024-03-13 08:59C:CYBN0.57News ReleaseCybin's CYB003 receives FDA breakthrough designation
2024-03-12 23:17C:CYBN0.58News ReleaseCybin to host call March 13 for CYB003 update
2024-02-14 12:40C:CYBN0.475News ReleaseCybin has cash of $39-million at Dec. 31
2024-02-14 07:40C:CYBN0.475SEDAR Interim MD & ASEDAR Interim MD & A
2024-02-14 07:34C:CYBN0.475SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-02-07 11:55C:CYBN0.395News ReleaseCybin receives two patents in Japan for DMT program
2024-01-23 09:05C:CYBN0.485News ReleaseCybin receives FDA OK to begin phase 2a CYB004 study
2024-01-08 11:46C:CYBN0.54News ReleaseCybin says CYB004, SPL028 well tolerated in phase 1
2024-01-04 10:54C:CYBN0.52News ReleaseCybin outlines phase 2 CYB003 results in MDD
2023-12-06 10:41C:CYBN0.57News ReleaseCybin receives U.S. patent for CYB003 program
2023-11-30 10:34C:CYBN0.64News ReleaseCybin boasts about CYB003 phase 2 safety, efficacy data
2023-11-16 12:46C:CYBN0.60News ReleaseCybin to release phase 2 CYB003 data Nov. 30
2023-11-14 19:32C:CYBN0.62News ReleaseCybin has cash of $18.1-million at Sept. 30